Matthew Stober

Matthew Stober brings to the Par Health Board deep expertise in technical and cross-functional execution, leadership in biologics operations, and a strong track record of driving innovation, operational transformation, and strategic growth across both clinical-stage and commercial life sciences organizations. 

Mr. Stober currently serves as Chief Executive Officer of Argenta, a global animal health Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), a position he assumed in September 2025.  

Previously, Mr. Stober held CEO positions at Abzena, a biologics and bioconjugate contract research and development services organization; CastelVax, a development-stage vaccine company; and Istari Oncology, a clinical-stage company focused on immune-oncology and immunotherapy. Earlier in his career, he held senior executive leadership roles at Hospira, Novartis, GlaxoSmithKline, and Merck.

Mr. Stober currently serves on the boards of Atlas Clinical Research and Gemini Bio, and has previously served on the boards of Leiters, Istari, CastelVax, and X-Vax Technology, Inc. 

He earned a Bachelor of Science in Chemical Engineering from Villanova University.